米国における抗肥満薬市場

Abstract

This research service covers the Anti-obesity Prescription Markets across the United States for the perios 2002 through 2012.

The research service provides a detailed analysis of the revenue structure across therapies. Strategic recommendations for these have also been discussed along with revenue forecasts.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

• 1. Introduction

2. INTRODUCTION TO U.S. ANTI-OBESITY PRESCRIPTION MARKETS

Introduction

• 1. Market Overview
• 2. Research Scope and Methodology

Basic Obesity Terminologies and Definitions

• 1. Obesity Definition
• 2. Obesity Classification
• 3. Obesity Etiology
• 4. Obesity Diagnosis

Market Dynamics

• 1. Analysis
• 2. Market Drivers
• 3. Market Restraints
• 4. Market Trends

Industry Challenges and Strategic Recommendations

• 1. Industry Challenges
• 2. Strategic Recommendations

Frost & Sullivan Awards

• 1. Industry Innovation and Advancement of the Year
• 2. Technology Innovation of the Year Award
• 3. Product Differentiation Innovation of the Year Award

3. MARKET SEGMENTATION

Disease and Treatment Overview

• 1. Obesity Prevalence Forecasts
• 2. Obesity Diagnosed and Treated Patient Forecasts
• 3. Obesity Patient Compliance
• 4. Obesity Comorbid Conditions
• 5. Unmet Needs in Obesity

Product Analysis

• 1. Overview of Marketed Products
• 2. Xenical and Meridia SWOT Analyses
• 3. Key Patent Expirations

Competitive and Pipeline Analysis

• 1. Competitive Landscape
• 2. Competitor Profiles
• 3. Pipeline Analysis
• 4. Anticipated Launch Dates
• 5. Alliances Acquisitions and Licensing Agreements

Market Forecasts

• 1. Revenue Forecasts and Assumptions
• 2. Pricing Trends
• 3. Market Share Analysis

4. APPENDIX

Decision Support Databases

• 1. Total Population
• 2. Prevalence of Diabetes Mellitus
• 3. Diabetes Incidence
• 4. Prevalence of Obesity
• 5. Mortality Due to Coronary Heart Disease